CervoMed to Present at the Emerging Growth Conference

Core Insights - CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders [3] - The company will present at the Emerging Growth Conference on October 22, 2025, with Matthew Winton, Ph.D., as the presenter [1][2] Company Overview - CervoMed is developing neflamapimod, an investigational orally administered small molecule that inhibits p38 mitogen-activated protein kinase alpha [3] - Neflamapimod aims to address synaptic dysfunction, a reversible aspect of neurodegenerative processes in disorders such as Dementia with Lewy Bodies (DLB) [3] - The company has recently completed a Phase 2b trial evaluating neflamapimod in patients with DLB [3]